[{"orgOrder":0,"company":"Chongqing Zhifei Biological Products","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chongqing Zhifei Biological Products","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Chongqing Zhifei Biological Products \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Chongqing Zhifei Biological Products \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by Chongqing Zhifei Biological Products

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Merck & Co

                          Deal Size : $14,800.0 million

                          Deal Type : Collaboration

                          Details : Under the collaboration, Zhifei will continue to purchase five vaccine products including, 4-valent and 9-valent HPV vaccine, Gardasil (recombinant human papillomavirus quadrivalent vaccine), pentavalent rotavirus vaccine and other agreed products from M...

                          Product Name : Gardasil

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 21, 2023

                          Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Merck & Co

                          Deal Size : $14,800.0 million

                          Deal Type : Collaboration

                          blank